Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a role?

6533b7d6fe1ef96bd1266642

RESEARCH PRODUCT

Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a role?

Alain Monnereau Sébastien Orazio Olivier Dejardin Sandra Le Guyader-peyrou Marc Maynadié Xavier Troussard

subject

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology Male 0301 basic medicine Pediatrics Multivariate analysis MESH: Registries MESH : Aged MESH: Comorbidity Comorbidity MESH : Lymphoma Large B-Cell Diffuse MESH: Aged 80 and over 0302 clinical medicine International Prognostic Index MESH : Child MESH: Child MESH : Population Surveillance [ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology MESH : Female Registries Young adult Child Aged 80 and over MESH: Aged MESH: Middle Aged MESH : Prognosis Relative survival MESH: Patient Outcome Assessment [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology Articles Hematology Middle Aged MESH : Adult Prognosis MESH : Patient Outcome Assessment 3. Good health MESH: Young Adult Population Surveillance MESH: Survival Analysis 030220 oncology & carcinogenesis MESH : Comorbidity Marital status Female France Lymphoma Large B-Cell Diffuse Non-Hodgkin Leukemia Adult medicine.medical_specialty Adolescent MESH : Male MESH: Factor Analysis Statistical MESH : Young Adult MESH : Factor Analysis Statistical MESH: Prognosis MESH: Population Surveillance MESH: Social Class Young Adult 03 medical and health sciences MESH : Adolescent Internal medicine MESH : Social Class medicine Humans MESH : Middle Aged MESH : Aged 80 and over MESH : France Survival analysis Aged MESH: Adolescent MESH: Humans business.industry MESH : Humans MESH: Adult medicine.disease Survival Analysis Comorbidity MESH: Male Patient Outcome Assessment MESH: France 030104 developmental biology Social Class MESH: Lymphoma Large B-Cell Diffuse MESH : Survival Analysis Factor Analysis Statistical business MESH: Female Diffuse large B-cell lymphoma MESH : Registries

description

IF 7.702; International audience; The survival of patients with diffuse large B-cell lymphoma has increased during the last decade as a result of addition of anti-CD20 to anthracycline-based chemotherapy. Although the trend is encouraging, there are persistent differences in survival within and between the USA and European countries suggesting that non-biological factors play a role. Our aim was to investigate the influence of such factors on relative survival of patients with diffuse large B-cell lymphoma. We conducted a retrospective, multicenter, registry-based study in France on 1165 incident cases of diffuse large B-cell lymphoma between 2002 and 2008. Relative survival analyses were performed and missing data were controlled with the multiple imputation method. In a multivariate analysis, adjusted for age, sex and International Prognostic Index, we confirmed that time period was associated with a better 5-year relative survival. The registry area, the medical specialty of the care department (onco-hematology versus other), the time to travel to the nearest teaching hospital, the place of treatment (teaching versus not-teaching hospital -borderline significance), a comorbidity burden and marital status were independently associated with the 5-year relative survival. Adjusted for first-course treatment, inclusion in a clinical trial and treatment discussion in a multidisciplinary meeting were strongly associated with a better survival outcome. In contrast, socio-economic status (determined using the European Deprivation Index) was not associated with outcome. Despite therapeutic advances, various non-biological factors affected the relative survival of patients with diffuse large B-cell lymphoma. The notion of lymphoma-specific expertise seems to be essential to achieve optimal care management and reopens the debate regarding centralization of these patients' care in hematology/oncology departments.

year	journal	country	edition	language
2017-03-01	Haematologica

https://doi.org/10.3324/haematol.2016.152918